Sohini Das, Anjali Singh, Sanket Koul

Stories by Sohini Das, Anjali Singh, Sanket Koul

Tylenol row may not hit India's pharma exports

Tylenol row may not hit India's pharma exports

Rediff.com   29 Sep 2025

Amid controversy over USPresident Donald Trump's comments linking the use of Tylenol and other related paracetamol products by pregnant women to autism in children, experts and industry executives say that since India's export of the drug to the US is less, it will hardly affect the country's pharma exports to America.

Drugmakers look to fill Rs 600 cr Novo vacuum

Drugmakers look to fill Rs 600 cr Novo vacuum

Rediff.com   25 Sep 2025

Indian drugmakers Eris Lifesciences, Wockhardt and Lupin are prepping to cash in when Danish company Novo Nordisk bows out of the human insulin pen market by the end of this year and creates an opportunity estimated to be worth Rs 600-800 crore in the domestic market. Some self-use disposable pens are pre-filled with insulin and others can be reused with new cartridges.

When Romance Meets The Rulebook: How Cos Deal With Workplace Relationships

When Romance Meets The Rulebook: How Cos Deal With Workplace Relationships

Rediff.com   24 Sep 2025

Romance may be personal, but when it enters the workplace, particularly in reporting hierarchies, it becomes a matter of governance.

SC Verdict Instills Hope For Real Estate Reforms

SC Verdict Instills Hope For Real Estate Reforms

Rediff.com   24 Sep 2025

'The directives to enhance last-mile funding, consider revival funds, and systemic reforms across the sector are expected to revive stalled projects, improve accountability, and accelerate the delivery of affordable and mid-income housing.'

Luxury Cars, Bikes Rev Up For Festival Season

Luxury Cars, Bikes Rev Up For Festival Season

Rediff.com   23 Sep 2025

Luxury carmakers are shifting into high gear with a mix of product launches, personalised experiences and lifestyle-led engagement.

Mankind taps OpenAI to institutionalise AI in ops

Mankind taps OpenAI to institutionalise AI in ops

Rediff.com   18 Sep 2025

Delhi-based pharma major Mankind Pharma on Wednesday announced a collaboration with OpenAI to institutionalise artificial intelligence (AI) across its value chain, making it one of the first few Indian pharmaceutical companies to fully integrate advanced AI into its core operations.

AHPI, Star Health in spat over cashless service

AHPI, Star Health in spat over cashless service

Rediff.com   15 Sep 2025

If cashless services are suspended, AHPI said, its member hospitals will continue to treat Star Health policyholders, but patients will have to pay upfront and later seek reimbursements directly from the insurer.

Patients to benefit from GST cut, but pharma firms may face margin pressure

Patients to benefit from GST cut, but pharma firms may face margin pressure

Rediff.com   12 Sep 2025

The rationalisation of goods and services tax (GST), announced on Wednesday, directly lowers the cost of everyday medical consumables, and also high-end therapies in oncology and rare diseases, helping reduce out-of-pocket patient expenditure and better adherence to medication.

Helped by GST move, PV sales growth may rebound to 7% by FY27: Maruti

Helped by GST move, PV sales growth may rebound to 7% by FY27: Maruti

Rediff.com   12 Sep 2025

The country's largest carmaker Maruti Suzuki India expects auto sales to bounce back to the glory days of 7 per cent growth by FY 27, helped by the proposed GST rate cut which is expected to bring down car prices by 3.5 to 8.5 per cent.

Rare Earth Magnet Crunch Persists For Automakers

Rare Earth Magnet Crunch Persists For Automakers

Rediff.com   11 Sep 2025

'Despite assurance from China, none of the companies have received supplies from Chinese sellers.'

Why Hospitals Are Spending Money On IT

Why Hospitals Are Spending Money On IT

Rediff.com   11 Sep 2025

60 per cent of hospitals are directing investments towards IT capability building, 50 per cent towards business intelligence tools and data lakes, and a significant share into AI-led use cases such as clinical documentation (72 per cent), decision support systems (64 per cent) and imaging (60 per cent).

How India's pharma cos plan to tackle steep US tariffs

How India's pharma cos plan to tackle steep US tariffs

Rediff.com   10 Sep 2025

As the potential threat of a steep 200 per cent tariff on pharmaceutical imports hangs in the air, analysts and industry insiders feel that focus on exports to non-US regions as well as domestic market will increase as a long-term trend. US President Donald Trump told CNBC's Squawk Box in the first week of August that planned tariffs on import of pharmaceutical products to the US could eventually reach up to 250 per cent.

Why Hotels Are Building Branded Residences

Why Hotels Are Building Branded Residences

Rediff.com   29 Aug 2025

'While the concept was introduced globally over four decades ago, branded residences have taken off now in India.'

Senior living market to reach $8 bn by 2030

Senior living market to reach $8 bn by 2030

Rediff.com   28 Aug 2025

With the rise in elderly population and increasing interest around the segment by developers, the senior living industry is poised to reach a market size of $8 billion by 2030 from the current $1.8 to $2 billion, according to a report by Association of Senior Living in India (ASLI) and JLL.

EV makers hope for festive spark to light up sales

EV makers hope for festive spark to light up sales

Rediff.com   27 Aug 2025

India may see its busiest EV festive season in 2025 with SUVs, luxury cars and scooters set to launch, but rare-earth supply bottlenecks risk delaying rollouts.

Pharma cos may see short-term price blip: Ind-Ra

Pharma cos may see short-term price blip: Ind-Ra

Rediff.com   27 Aug 2025

Any potential tariffs on pharmaceutical imports into the US are unlikely to impact the credit profiles of Indian firms except for a short-term pricing blip, according to a report by India Ratings and Research (Ind-Ra). The report stated that the US generics market contributes around 35 per cent to the total revenue of the leading Indian pharma firms.

It's Pouring Car Discounts!

It's Pouring Car Discounts!

Rediff.com   18 Aug 2025

For hatchbacks and sedans, offers range between Rs 40,000 and Rs 80,000 while SUVs and multi-purpose vehicles carry benefits exceeding Rs 1 lakh.

25% Donald Trump tariff likely to weigh on pharma margins: Analysts

25% Donald Trump tariff likely to weigh on pharma margins: Analysts

Rediff.com   12 Aug 2025

If pharmaceutical exports from India to the US come under a 25 per cent tariff bracket, the impact on earnings before interest, tax, depreciation and amortisation (Ebitda) could be around 5 per cent, felt analysts. This is after assuming that about 75 per cent of the tariff would be passed on.

Indian Pharma Majors Ready With Weight Loss Drugs

Indian Pharma Majors Ready With Weight Loss Drugs

Rediff.com   12 Aug 2025

Prices for Indian consumers are expected to come down significantly from the current Rs 17,000-Rs 26,000 monthly.

EV car sales nearly double in July; two-wheeler demand slips: FADA data

EV car sales nearly double in July; two-wheeler demand slips: FADA data

Rediff.com   10 Aug 2025

Retail sales of electric passenger vehicles (ePVs) nearly doubled in July 2025, surging 93 per cent year-on-year (Y-o-Y) to 15,528 units, even as overall passenger vehicle (PV) retail volumes declined marginally. In contrast, electric two-wheeler (e2W) sales dropped by 4.3 per cent to 102,973 units, according to the Federation of Automobile Dealers Associations (Fada) data.